BioCentury | Jan 18, 2016
Company News
Cour Pharmaceutical, Takeda deal
...cooperation with Northwestern University (Evanston, Ill.). Takeda will have an exclusive option to globally license TIMP/Gliadin...
...Phase IIa trial and an option to collaborate on up to three additional TIMP compounds. TIMP/Gliadin...
...Phase IIa trial and an option to collaborate on up to three additional TIMP compounds. TIMP/Gliadin...